Carbohydrate Metabolic Disorder

Categories: Metabolic diseases

Aliases & Classifications for Carbohydrate Metabolic Disorder

MalaCards integrated aliases for Carbohydrate Metabolic Disorder:

Name: Carbohydrate Metabolic Disorder 12 15
Carbohydrate Metabolism, Inborn Errors 44 73
Disorder of Carbohydrate Metabolism 29 73
Disorder of Carbohydrate Transport and Metabolism 12
Inborn Errors of Carbohydrate Metabolism 12
Inborn Carbohydrate Metabolism Disorder 12
Carbohydrate Metabolism Disorders 43
Carbohydrate Metabolism Disorder 55


External Ids:

Disease Ontology 12 DOID:2978
ICD9CM 35 271.8
MeSH 44 D002239
ICD10 33 E74 E74.8

Summaries for Carbohydrate Metabolic Disorder

MedlinePlus : 43 Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process. Carbohydrate metabolism disorders are a group of metabolic disorders. Normally your enzymes break carbohydrates down into glucose (a type of sugar). If you have one of these disorders, you may not have enough enzymes to break down the carbohydrates. Or the enzymes may not work properly. This causes a harmful amount of sugar to build up in your body. That can lead to health problems, some of which can be serious. Some of the disorders are fatal. These disorders are inherited. Newborn babies get screened for many of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. Treatments may include special diets, supplements, and medicines. Some babies may also need additional treatments, if there are complications. For some disorders, there is no cure, but treatments may help with symptoms.

MalaCards based summary : Carbohydrate Metabolic Disorder, also known as carbohydrate metabolism, inborn errors, is related to fructose-1,6-bisphosphatase deficiency and galactosemia. An important gene associated with Carbohydrate Metabolic Disorder is INS (Insulin), and among its related pathways/superpathways are Metabolism and Glycosaminoglycan metabolism. The drugs Cyclophosphamide and Dihydroartemisinin have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and kidney, and related phenotypes are Increased transferrin (TF) endocytosis and Apoptosis resistance

Disease Ontology : 12 An inherited metabolic disorder that affect the catabolism and anabolism of carbohydrates.

Related Diseases for Carbohydrate Metabolic Disorder

Diseases related to Carbohydrate Metabolic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 fructose-1,6-bisphosphatase deficiency 32.3 AGL ALDOB G6PC
2 galactosemia 32.0 ALDOB G6PC GALK1 GALT
3 galactose epimerase deficiency 30.8 GALK1 GALT
4 galactokinase deficiency 30.6 GALK1 GALT
5 pyruvate dehydrogenase e1-alpha deficiency 11.2
6 pentosuria 11.1
7 congenital disorder of glycosylation, type in 10.9
8 congenital disorder of deglycosylation 10.9
9 juvenile spinal muscular atrophy 10.9
10 hyperinsulinemic hypoglycemia 10.9
11 glucosephosphate dehydrogenase deficiency 10.9
12 proximal spinal muscular atrophy 10.9
13 mucopolysaccharidosis, type ii 10.9
14 epimerase deficiency galactosemia 10.7 GALK1 GALT
15 glycogen storage disease vi 10.6 G6PC PYGM
16 phosphoglycerate kinase deficiency 10.4 PFKM PYGM
17 lactose intolerance 10.3 ALDOB LCT
18 factitious disorder 10.3 ABCC8 INS
19 glycogen storage disease v 10.2 GAA PFKM PYGM
20 hyperinsulinemic hypoglycemia, familial, 2 10.2 ABCC8 INS
21 hyperuricemia 10.2 G6PC INS PFKM
22 atrial standstill 1 10.2 AGL GAA GBE1
23 fanconi-bickel syndrome 10.2 ABCC8 G6PC INS
24 renal glucosuria 10.2
25 biotin deficiency 10.1 BTD HLCS
26 acute insulin response 10.1 ABCC8 INS PYGM
27 endocrine pancreas disease 10.1 ABCC8 G6PC INS
28 holocarboxylase synthetase deficiency 10.1 AGL BTD HLCS
29 glucose metabolism disease 10.1 ABCC8 G6PC INS
30 glycogen storage disease iii 10.1 AGL G6PC GAA GBE1
31 glycogen storage disease iv 10.1 AGL G6PC GAA GBE1
32 multiple carboxylase deficiency 10.1 BTD HLCS
33 monocarboxylate transporter 1 deficiency 10.0 HLCS INS
34 glycogen storage disease vii 10.0 GBE1 PFKM PYGM
35 hyperglycemia 10.0 ABCC8 G6PC INS
36 pyruvate carboxylase deficiency 10.0
37 fructose intolerance, hereditary 9.9
38 fructosuria, essential 9.9
39 pyruvate dehydrogenase e2 deficiency 9.9
40 pyruvate dehydrogenase e3-binding protein deficiency 9.9
41 dihydrolipoamide dehydrogenase deficiency 9.9
42 pyruvate dehydrogenase phosphatase deficiency 9.9
43 pyruvate dehydrogenase e1-beta deficiency 9.9
44 mitochondrial pyruvate carrier deficiency 9.9
45 pepck 1 deficiency 9.9
46 glycogen storage disease due to lactate dehydrogenase deficiency 9.9
47 generalized galactose epimerase deficiency 9.9
48 erythrocyte galactose epimerase deficiency 9.9
49 diabetes mellitus 9.8
50 hypoglycemia 9.8 ABCC8 AGL G6PC INS

Graphical network of the top 20 diseases related to Carbohydrate Metabolic Disorder:

Diseases related to Carbohydrate Metabolic Disorder

Symptoms & Phenotypes for Carbohydrate Metabolic Disorder

GenomeRNAi Phenotypes related to Carbohydrate Metabolic Disorder according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.36 LCT PFKM PHKA2 PMM2 AGXT ALDOB
2 Apoptosis resistance GR00093-A-0 9.13 G6PC PFKM PHKA2

MGI Mouse Phenotypes related to Carbohydrate Metabolic Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 GALK1 GALT GBE1 GRHPR HOGA1 INS
2 liver/biliary system MP:0005370 9.7 HOGA1 INS PMM2 AGL ALDOB G6PC
3 muscle MP:0005369 9.56 AGL BTD GAA GBE1 INS PFKM
4 renal/urinary system MP:0005367 9.23 AGXT BTD G6PC GRHPR HOGA1 INS

Drugs & Therapeutics for Carbohydrate Metabolic Disorder

Drugs for Carbohydrate Metabolic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3 50-18-0, 6055-19-2 2907
Dihydroartemisinin Approved, Investigational Phase 4 71939-50-9 6918483
Piperaquine Approved, Investigational Phase 4 4085-31-8 5079497
Primaquine Approved Phase 4,Phase 1,Not Applicable 90-34-6 4908
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
rituximab Approved Phase 4,Phase 2,Phase 1 174722-31-7 10201696
Dapsone Approved, Investigational Phase 4 80-08-0 2955
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 1 54-05-7 2719
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
12 Antioxidants Phase 4,Not Applicable
Bilirubin Phase 4 635-65-4 5280352
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Caseins Phase 4
18 Chelating Agents Phase 4
19 Anti-Infective Agents Phase 4,Phase 1,Phase 2,Not Applicable
20 Antimalarials Phase 4,Phase 1,Not Applicable
21 Antiparasitic Agents Phase 4,Phase 1,Not Applicable
22 Antiprotozoal Agents Phase 4,Phase 1,Not Applicable
23 Artemisinine Phase 4
24 Artemisinins Phase 4
25 Adrenergic Agents Phase 4,Phase 1,Phase 2
26 Adrenergic Agonists Phase 4,Phase 1,Phase 2
27 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 1,Phase 2
28 Adrenergic beta-Agonists Phase 4,Phase 1,Phase 2
29 Albuterol Phase 4,Phase 1,Phase 2
30 Anti-Asthmatic Agents Phase 4,Phase 1,Phase 2
31 Autonomic Agents Phase 4,Phase 1,Phase 2
32 Bronchodilator Agents Phase 4,Phase 1,Phase 2
33 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Early Phase 1
34 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
35 Respiratory System Agents Phase 4,Phase 1,Phase 2
36 Tocolytic Agents Phase 4,Phase 1,Phase 2
37 Antibodies Phase 4,Phase 1,Phase 2
38 Immunoglobulins Phase 4,Phase 1,Phase 2
39 Antimetabolites Phase 4,Phase 1,Phase 2
40 Antimetabolites, Antineoplastic Phase 4,Phase 1,Phase 2
41 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Dermatologic Agents Phase 4,Phase 1,Phase 2
43 Folic Acid Antagonists Phase 4
44 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
45 Vitamin B Complex Phase 4,Phase 2,Not Applicable
46 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
47 Alkylating Agents Phase 4,Phase 2,Phase 3
48 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 3
49 Analgesics Phase 4,Phase 1
50 Analgesics, Non-Narcotic Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 401)
# Name Status NCT ID Phase Drugs
1 Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
2 CPAP for Infantile Pompe Disease Unknown status NCT02405624 Phase 4
3 Incidence of Lactose Intolerance Among Self-reported Lactose Intolerant People Completed NCT02878876 Phase 4
4 Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance Completed NCT02636413 Phase 4 gaxilose
5 Effects Comparison of A1 and A2 Milk on Gastrointestinal Physiology, Symptoms and Cognitive Behavior Completed NCT02406469 Phase 4
6 Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Completed NCT00607386 Phase 4
7 Safety and Tolerability of Low Dose Primaquine Completed NCT02434952 Phase 4 Dihydroartemisinin piperaquine (DHA PP);Primaquine
8 Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease Completed NCT02405598 Phase 4 Salbutamol
9 A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI Completed NCT00299000 Phase 4 Naglazyme
10 A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease Completed NCT00144781 Phase 4
11 A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients Completed NCT00144768 Phase 4 laronidase
12 Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa Completed NCT01288027 Phase 4
13 An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Completed NCT00701129 Phase 4 Methotrexate;Rituximab
14 High Dose or High Dose Frequency Study of Alglucosidase Alfa Completed NCT00483379 Phase 4
15 Late-Onset Treatment Study Extension Protocol Completed NCT00455195 Phase 4
16 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4 ACZONE Gel, 5%;Vehicle
17 A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants Recruiting NCT00418821 Phase 4
18 Immune Modulation Therapy for Pompe Disease Recruiting NCT02525172 Phase 4 Rituximab;intravenous immune globulin;Bortezomib;Methotrexate
19 Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease Recruiting NCT01410890 Phase 4
20 Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Active, not recruiting NCT02455622 Phase 4 Elaprase for intravenous (IV) infusion
21 Immune Tolerance Induction Study Active, not recruiting NCT00701701 Phase 4
22 Growth and Development Study of Alglucosidase Alfa. Active, not recruiting NCT00486889 Phase 4
23 Assessing a Risk Model for G6PD Deficiency Not yet recruiting NCT03337152 Phase 4 primaquine;chloroquine + primaquine
24 Morquio's Syndrome: a Case Study Terminated NCT00609440 Phase 4
25 A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease Terminated NCT01597596 Phase 4
26 A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease Terminated NCT01526785 Phase 4 Alglucosidase alfa
27 A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency Withdrawn NCT02784067 Phase 4 Sucraid;Placebo
28 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
29 BMN 110 Phase 3B in Australian Patients Unknown status NCT01966029 Phase 3 BMN 110
30 Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation Unknown status NCT02498340 Phase 2, Phase 3
31 Evaluation of Long-term Efficacy of Treatment With Lamazym Completed NCT02478840 Phase 3 Lamazym
32 A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis Completed NCT01681953 Phase 3 Lamazym;Placebo
33 A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) Completed NCT02230566 Phase 3 UX003
34 A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01275066 Phase 3 BMN 110 Weekly;Placebo;BMN 110 Every Other Week
35 Study of rhASB in Patients With Mucopolysaccharidosis VI Completed NCT00104234 Phase 3 N-acetylgalactosamine 4-sulfatase;Placebo/rhASB
36 Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) Completed NCT00069641 Phase 2, Phase 3
37 Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI Completed NCT00067470 Phase 3 Placebo;N-acetylgalactosamine 4-sulfatase
38 Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01415427 Phase 3 BMN 110 - Weekly;BMN 110 - Every Other Week
39 Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance Completed NCT02673749 Phase 2, Phase 3 RP-G28
40 Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I Completed NCT00912925 Phase 3
41 Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Completed NCT00630747 Phase 2, Phase 3
42 Phase 2/3 Oxabact Study Completed NCT01037231 Phase 2, Phase 3 Placebo
43 Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease Completed NCT00258011 Phase 3
44 Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients Completed NCT00146770 Phase 3
45 Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Completed NCT02055118 Phase 2, Phase 3
46 Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients Completed NCT00638703 Phase 2, Phase 3 Placebo
47 A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia Completed NCT01145586 Phase 3 Lactase Oral Tablets
48 A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI) Completed NCT01145339 Phase 3 Lactase
49 Safety and Efficacy of Hunterase Completed NCT01645189 Phase 3
50 Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support Completed NCT00268944 Phase 3

Search NIH Clinical Center for Carbohydrate Metabolic Disorder

Cochrane evidence based reviews: carbohydrate metabolism, inborn errors

Genetic Tests for Carbohydrate Metabolic Disorder

Genetic tests related to Carbohydrate Metabolic Disorder:

# Genetic test Affiliating Genes
1 Disorder of Carbohydrate Metabolism 29

Anatomical Context for Carbohydrate Metabolic Disorder

MalaCards organs/tissues related to Carbohydrate Metabolic Disorder:

Testes, Bone, Kidney, Brain, Bone Marrow, Liver, Tongue

Publications for Carbohydrate Metabolic Disorder

Articles related to Carbohydrate Metabolic Disorder:

(show all 13)
# Title Authors Year
Disorders of carbohydrate metabolism in experimental brain injury. ( 29975470 )
Protective effects of vescalagin from pink wax apple [Syzygium samarangense (Blume) Merrill and Perry] fruit against methylglyoxal-induced inflammation and carbohydrate metabolic disorder in rats. ( 23819528 )
[Carbohydrate metabolism disorders among obese children and adolescents. Diabetes mellitus type 2]. ( 23529596 )
Hashimoto's thyroiditis and carbohydrate metabolism disorders in patients hospitalised in the Department of Endocrinology and Diabetology of Ludwik Rydygier Collegium Medicum in Bydgoszcz between 2001 and 2010. ( 22378092 )
[Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension]. ( 15759454 )
[Disorder of carbohydrate metabolism]. ( 15206146 )
[Comparative diagnostic characteristics of carbohydrate metabolism disorders in women with polycystic ovary syndrome (PCOS)]. ( 14577361 )
[Characteristics of lipid profile in blood plasma of patients with metabolic syndrome and manifest disorder of carbohydrate metabolism]. ( 14669600 )
[Diagnostic criteria of carbohydrate metabolism disorders in pulmonary tuberculosis complicated by diabetes mellitus in patients with various haptoglobin phenotypes]. ( 11338533 )
[Carbohydrate metabolic disorder in women with a neuroendocrine syndrome]. ( 8017575 )
[Determination of fructosamine in the early diagnosis of disorders of carbohydrate metabolism]. ( 7740029 )
[Glycosylated proteins and the rheological properties of the erythrocytes in carbohydrate metabolic disorders]. ( 1803588 )
Autotransplantation of pancreatic tail tissue to prevent carbohydrate metabolic disorder following total pancreatectomy. A case report with preliminary experience. ( 6816515 )

Variations for Carbohydrate Metabolic Disorder

Expression for Carbohydrate Metabolic Disorder

Search GEO for disease gene expression data for Carbohydrate Metabolic Disorder.

Pathways for Carbohydrate Metabolic Disorder

Pathways related to Carbohydrate Metabolic Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
5 11.7 G6PC PHKA2 PYGM
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11 11.18 AGL GBE1 PHKA2 PYGM
13 9.91 BTD HLCS

GO Terms for Carbohydrate Metabolic Disorder

Cellular components related to Carbohydrate Metabolic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.32 ALDOB BTD GAA GALK1 GBE1 GRHPR

Biological processes related to Carbohydrate Metabolic Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 metabolic process GO:0008152 9.91 AGL GAA GALK1 GRHPR HLCS HOGA1
2 carbohydrate metabolic process GO:0005975 9.76 GAA GALK1 GALT GBE1 INS LCT
3 glucose homeostasis GO:0042593 9.67 G6PC INS PFKM
4 glycogen biosynthetic process GO:0005978 9.56 AGL GBE1
5 canonical glycolysis GO:0061621 9.55 ALDOB PFKM
6 carbohydrate phosphorylation GO:0046835 9.54 GALK1 PFKM
7 cellular nitrogen compound metabolic process GO:0034641 9.52 AGXT GRHPR
8 muscle cell cellular homeostasis GO:0046716 9.51 GAA PFKM
9 glyoxylate metabolic process GO:0046487 9.5 AGXT GRHPR HOGA1
10 biotin metabolic process GO:0006768 9.48 BTD HLCS
11 galactose metabolic process GO:0006012 9.46 GALK1 GALT
12 galactose catabolic process GO:0019388 9.43 GALK1 GALT
13 glycogen metabolic process GO:0005977 9.43 AGL G6PC GAA GBE1 PHKA2 PYGM
14 pyruvate biosynthetic process GO:0042866 9.4 AGXT HOGA1
15 glyoxylate catabolic process GO:0009436 9.37 AGXT HOGA1
16 glycogen catabolic process GO:0005980 9.1 AGL G6PC GAA PFKM PHKA2 PYGM

Molecular functions related to Carbohydrate Metabolic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.91 AGL AGXT GALK1 GALT GBE1 PFKM
2 hydrolase activity, acting on glycosyl bonds GO:0016798 9.43 AGL GAA LCT
3 catalytic activity GO:0003824 9.35 GAA HLCS LCT PFKM PYGM
4 phosphotransferase activity, alcohol group as acceptor GO:0016773 9.32 G6PC GALK1
5 fructose binding GO:0070061 9.16 ALDOB PFKM
6 hydrolase activity, hydrolyzing O-glycosyl compounds GO:0004553 8.8 GAA GBE1 LCT

Sources for Carbohydrate Metabolic Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....